Cargando…
MicroRNA and vascular smooth muscle cell phenotype: new therapy for atherosclerosis?
MicroRNAs (miRNAs) represent a class of small, non-coding RNAs that negatively regulate gene expression via degradation or translational inhibition of their target mRNAs. Recent studies have identified that miR-145 is the most abundant miRNA in normal arteries and vascular smooth muscle cells (VSMCs...
Autor principal: | |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2768992/ https://www.ncbi.nlm.nih.gov/pubmed/19744308 http://dx.doi.org/10.1186/gm85 |
_version_ | 1782173537270759424 |
---|---|
author | Zhang, Chunxiang |
author_facet | Zhang, Chunxiang |
author_sort | Zhang, Chunxiang |
collection | PubMed |
description | MicroRNAs (miRNAs) represent a class of small, non-coding RNAs that negatively regulate gene expression via degradation or translational inhibition of their target mRNAs. Recent studies have identified that miR-145 is the most abundant miRNA in normal arteries and vascular smooth muscle cells (VSMCs), and its expression is significantly downregulated in dediffer-entiated VSMCs and atherosclerotic arteries. miR-145 plays a critical role in modulating VSMC phenotype. Because phenotypic modulation of VSMCs is an initial cellular event in the development of atherosclerosis, miRNAs, and miR-145 in particular, may represent new therapeutic targets for atherosclerosis. |
format | Text |
id | pubmed-2768992 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-27689922010-09-09 MicroRNA and vascular smooth muscle cell phenotype: new therapy for atherosclerosis? Zhang, Chunxiang Genome Med Minireview MicroRNAs (miRNAs) represent a class of small, non-coding RNAs that negatively regulate gene expression via degradation or translational inhibition of their target mRNAs. Recent studies have identified that miR-145 is the most abundant miRNA in normal arteries and vascular smooth muscle cells (VSMCs), and its expression is significantly downregulated in dediffer-entiated VSMCs and atherosclerotic arteries. miR-145 plays a critical role in modulating VSMC phenotype. Because phenotypic modulation of VSMCs is an initial cellular event in the development of atherosclerosis, miRNAs, and miR-145 in particular, may represent new therapeutic targets for atherosclerosis. BioMed Central 2009-09-09 /pmc/articles/PMC2768992/ /pubmed/19744308 http://dx.doi.org/10.1186/gm85 Text en Copyright ©2009 BioMed Central Ltd |
spellingShingle | Minireview Zhang, Chunxiang MicroRNA and vascular smooth muscle cell phenotype: new therapy for atherosclerosis? |
title | MicroRNA and vascular smooth muscle cell phenotype: new therapy for atherosclerosis? |
title_full | MicroRNA and vascular smooth muscle cell phenotype: new therapy for atherosclerosis? |
title_fullStr | MicroRNA and vascular smooth muscle cell phenotype: new therapy for atherosclerosis? |
title_full_unstemmed | MicroRNA and vascular smooth muscle cell phenotype: new therapy for atherosclerosis? |
title_short | MicroRNA and vascular smooth muscle cell phenotype: new therapy for atherosclerosis? |
title_sort | microrna and vascular smooth muscle cell phenotype: new therapy for atherosclerosis? |
topic | Minireview |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2768992/ https://www.ncbi.nlm.nih.gov/pubmed/19744308 http://dx.doi.org/10.1186/gm85 |
work_keys_str_mv | AT zhangchunxiang micrornaandvascularsmoothmusclecellphenotypenewtherapyforatherosclerosis |